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Abstract
Introduction We assessed the in vivo effects of terbutaline, a
beta2-agonist assumed to reduce microvascular permeability in
acute lung injury.
Methods We used a recently developed broncho-alveolar
lavage (BAL) technique to repeatedly measure (every 15 min. for
4 hours) the time-course of capillary-alveolar leakage of a
macromolecule (fluorescein-labeled dextran) in 19 oleic acid
(OA) lung injured dogs. BAL was performed in a closed lung
sampling site, using a bronchoscope fitted with an inflatable
cuff. Fluorescein-labeled Dextran (FITC-D70) was continuously
infused and its concentration measured in plasma and BAL fluid.
A two-compartment model (blood and alveoli) was used to
calculate KAB, the transport rate coefficient of FITC-D70 from
blood to alveoli. KAB was estimated every 15 minutes over 4
hours. Terbutaline intra-venous perfusion was started 90 min.
after the onset of the injury and then continuously infused until
the end of the experiment.
Results In the non-treated injured group, the capillary-alveolar
leakage of FITC-D70 reached a peak within 30 minutes after the
OA injury. Thereafter the FITC-D70 leakage decreased
gradually until the end of the experiment. Terbutaline infusion,
started 90 min after injury, interrupted the recovery with an
aggravation in FITC-D70 leakage.
Conclusions As cardiac index increased with terbutaline
infusion, we speculate that terbutaline recruits leaky capillaries
and increases FITC-D70 leakage after OA injury. These findings
suggest that therapies inducing an increase in cardiac output
and a decrease in pulmonary vascular resistances have the
potential to heighten the early increase in protein transport from
plasma to alveoli within the acutely injured lung.
Introduction
Acute lung injury (ALI) is a major syndrome in patients in the
intensive care unit, and it has a high mortality rate. An
increased capillary-alveolar permeability to plasma proteins is
an early marker of the acute phase of lung injury andcontrib-
utes to the development of fibroproliferation [1]and lung fibro-
sis, which both contribute to a negative outcome [2]. Plasma
proteins that flood the alveoli include pro-coagulant factors
and initiate a local coagulation cascade [3]. A relation
between the early alteration of capillary-alveolar permeability
to proteins and the fibrotic process has been confirmed in clin-
ical studies [4]. The finding that in acute respiratory distress
syndrome (ARDS) patients, bronchoalveolar lavage (BAL) pro-
tein levels decreased over time only in survivors suggests the
involvement of the amplification of inflammatory responses
due to alveolar protein flooding [5]. If a high BAL protein con-
centration in patients with ARDS predicts a higher risk of late
fibrosis, any therapy aimed at reducing plasma protein accu-
mulation in the interstitium and alveoli is of potential benefit.
ABP: systemic arterial blood pressure; ALI: acute lung injury; ALTA: AlbuteroL for the Treatment of ALI; ANOVA: analysis of variance; ARDS: acute 
respiratory distress syndrome; BAL: broncho-alveolar lavage; BALTI: Beta-Agonist Lung Injury Trial; CO: cardiac output; FiO2: fraction of inspired 
oxygen; FITC-D70: fluorescein-labeled dextran; Hcl: Hydrochloric acid; KAB: coefficient of capillary-alveolar leakage; OA: oleic acid; PaO2: partial 
pressure of oxygen in arterial blood; PAOP: pulmonary arterial occlusion pressure; PAP: pulmonary arterial blood pressure; Pcap: pulmonary capillary 
pressure; PET: Positron emission tomography; PVR: total pulmonary vascular resistances; SEM: standard error of the mean; SpO2: pulsed oxygen 
saturation; Vtn: volume of the lavaged lung segment.Critical Care    Vol 13 No 5    Briot et al.
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We recently developed a modified BAL technique to monitor
the capillary-alveolar leakage of macromolecules over several
hours [6]. This technique allows the assessment of therapies
aimed at slowing plasma protein accumulation in alveoli.
Several studies suggest a potential role for β2-agonists in the
treatment of ARDS. These agents have been shown to reduce
pulmonary neutrophil sequestration and activation, enhance
surfactant secretion and modulate the inflammatory and coag-
ulation cascades [7,8]. β2-adrenergic agonists have shown
ability to reduce lung endothelial injury [9]and they are well
known for their ability to enhance the epithelial fluid reabsorp-
tion by stimulating the activity and the expression of the epithe-
lial sodium channels [10]. However, the results of clinical
studies on β2-agonists effects in ARDS are controversial. The
Beta-Agonist Lung Injury Trial (BALTI) [11]showed that intra-
venous albuterol treatment reduces extravascular lung water in
patients with ARDS; but the recent study "AlbuteroL for the
Treatment of ALI" (ALTA) [12] failed to find a beneficial effect
of aerosolized albuterol therapy in a large randomized, pla-
cebo-controlled trial. Also, several in vivo studies showed no
beneficial effects of β2-agonist therapy, in terms of protein
accumulation in injured lungs [13,14]. Hemodynamic effects
of β2-agonists may interfere with other potentially beneficial
effects and may explain some of these contradictory results in
patients with lung injury [15].
The goal of the present study was therefore to evaluate the
effects of terbutaline, a widely used β2-agonist, on the early
increase in macromolecular permeability of the capillary-alveo-
lar barrier following lung injury. We used a well-known in vivo
dog model of oleic acid (OA) lung injury in which we assessed
the overall effect of terbutaline, both on protein leakage
through the capillary-alveolar barrier and on pulmonary
hemodynamics.
Materials and methods
Animal preparation
The experiments were performed on 19 anesthetized dogs.
The experiments were carried out in accordance with the
applicable French and European Community regulations. Ani-
mals were intubated and mechanically ventilated using 2%
halothane to maintain anesthesia. Tidal volume was 10 mL/kg
and respiratory frequency was adjusted between 12 and 20
breathes/minute to keep end-tidal CO2 within normal range.
Fraction of inspired oxygen (FiO2) was adjusted to keep hemo-
globin oxygen saturation above 95%, as measured by pulse
oxymetry (SpO2). Arterial blood gases were measured every
hour following a 10-minute period of ventilation with an FiO2 of
100%.
In injury experiments, animals were equipped with a pulmonary
artery catheter and a catheter in the femoral artery. The follow-
ing parameters were recorded: systemic arterial blood pres-
sure (ABP), pulmonary arterial blood pressure (PAP),
pulmonary arterial occlusion pressure (PAOP), and cardiac
output (CO). Pulmonary capillary pressure (Pcap) was esti-
mated from the back-extrapolation of the transitory pressure
drop (between 0.2 and 2 seconds) following the inflation of
the balloon of the pulmonary arterial catheter, using a double-
exponential fit [16]. As control animals were destined for other
later experiments, they were not equipped with invasive
catheters.
Broncho-alveolar lavage procedure
This modified BAL technique has been extensively described
in a previous publication [6]. Briefly, in order to perform
repeated BAL in a closed lung segment, an inflatable balloon
was adapted to the extremity of a bronchoscope. Six initial
BAL cycles were performed sequentially, in order to obtain a
rapid saturation of the lavaged lung segment. Thereafter, one
BAL cycle was performed every 15 minutes for the next three
hours.
Sample processing
Prior to the procedure, a batch solution of 500 mL of fresh lav-
age fluid was prepared by adding 125I-albumin (Cis Bio Inter-
national, Paris, France) to saline (NaCl: 0.9 g %) at a final
activity of 5 μCi/L as a dilution indicator of the lavage fluid
inside the lung.
Thirty minutes before BAL, a 6 mg/kg bolus of a fluorescein
isothiocyanate-labeled dextran (FITC-D70; average molecular
mass, 73,100 daltons; Sigma, St. Quentin Fallavier, France)
was injected, followed by an infusion of 6 mg/kg/hour in order
to obtain a steady FITC-D70 concentration in plasma. Indica-
tor concentrations were measured after the experiment. 125I-
albumin activity was measured in BAL. FITC-D70 concentra-
tions were measured in plasma and BAL fluid by fluorescence
spectrophotometry,  using excitation and emission wave-
lengths of 482 and 521 nm, respectively. The data analysis
was performed using a two-compartment model where the
FITC-D70 transport rate coefficient KAB (min-1) from blood to
alveoli was estimated (see details of calculations in Additional
data file 1).
Experimental protocol
The study was performed in four separate groups.
In group 1 (n = 3) control animals were not injured with OA
and received no terbutaline. In group 2 (n = 3) animals were
not injured but received a terbutaline treatment.
In groups 3 and 4 the ALI was induced 30 minutes after the
initial saturation BAL procedure. Every two minutes, 0.3 ml
boluses of OA were injected into the superior vena cava
through the proximal lumen of the pulmonary artery catheter up
to a total dose of 0.08 ml/kg. Group 3 (n = 7) received OA
injury without any treatment. In group 4 (n = 6) the terbutaline
treatment was administered using an infusion of 0.25 mg/kg/Available online http://ccforum.com/content/13/5/R166
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min started 90 minutes after OA injury. Thereafter the terbuta-
line was continuously infused until the end of the experiment.
Statistics
A statistical analysis was performed through Statview soft-
ware (SAS Institute Inc. Cary, NC, USA). Group data are sum-
marized as the mean ± standard error of the mean (SEM). First
we compared global data by analysis of variance (ANOVA).
Thereafter intra-group data were compared using a post-hoc
test of Tukey-Kramer. Mann-Whitney rank-sum tests were
used for two-group comparisons. We used linear regression
models to determine individual correlations between KAB and
hemodynamic data. Differences with a P < 0.05 were consid-
ered as significant.
Results
The volume of the lavaged lung segment (Vtn) remained stable
(63.1 ± 3.1 mL) throughout the sequential lavage cycles. The
FITC-D70 plasma concentration was also stable throughout
the experiment (0.15 ± 0.01 mg/mL).
The alveolar concentration of FITC-D70 remained near zero in
all groups before the onset of the injury. In injured animals
(groups 3 and 4), the alveolar FITC-D70 concentration rose
immediately after the OA infusion. In group 3 (OA) the FITC-
D70 concentration reached a plateau during the last hour of
the experiment, whereas in group 4 (OA + terbutaline) the
start of terbutaline perfusion was followed by a second rise in
BAL FITC-D70 concentration (Figure 1).
Coefficient of capillary-alveolar leakage (KAB)
The FITC-D70 capillary-alveolar transport rate coefficient from
blood to alveoli (KAB) was near zero in groups 3 and 4 before
OA injury, a period defined as steady state.
Although KAB remained near zero in control groups 1 and 2
throughout the experiment, this coefficient rose markedly in
OA-injured animals (groups 3 and 4) immediately after the
onset of injury. KAB reached a peak value (peak of injury) 30
minutes after the OA infusion and decreased gradually there-
after. Within this recovery period, we distinguished two
phases: early recovery (first 45 minutes after the peak of injury)
and late recovery (last hour of the experiment).
In group 3 (OA injury) KAB recovered slowly, while in group 4
(OA + terbutaline) KAB rose again after the onset of terbutaline
administration (Figure 2).
Hemodynamics values
In group 4 (OA + terbutaline) the cardiac index and the PAP
increased and remained elevated following terbutaline admin-
istration. Such an increase was not observed in group 3 (OA).
Total pulmonary vascular resistances (PVR) increased after
OA injury and remained elevated in non-treated animals (group
3). Terbutaline infusion reduced the elevated PVR approxi-
mately to the pre-injury level. The hematocrit was constant
throughout the experiment (mean value, 0.36 ± 0.1) with no
significant difference between the different groups. The partial
pressure of arterial oxygen (PaO2)/FiO2 ratio decreased mark-
edly at the onset of the injury and did not recover later. There
Figure 1
FITC-D70 concentration in broncho-alveolar lavage FITC-D70 concentration in broncho-alveolar lavage. Open circles = 
group 1 which was a control group (n = 3); Open squares = group 2 
which was a control group with terbutaline infusion (n = 3); Filled cir-
cles = group 3 which was the OA injury group (n = 7); Filled squares = 
group 4 which was the OA injury with late terbutaline infusion group (n 
= 6). * P < 0.05 early recovery versus late recovery in group 4 (OA + 
terbutaline) (intra-group comparison by analysis of variance and the 
post-hoc test of Tukey-Kramer). FITC-D70 = fluorescein-labeled dex-
tran; OA = oleic acid.
Figure 2
Time course of KAB, the transport rate constant for FITC-D70 from  blood to alveoli Time course of KAB, the transport rate constant for FITC-D70 from 
blood to alveoli. Open circles = group 1 which was a control group (n 
= 3); Open squares = group 2 which was a control group with terbuta-
line infusion (n = 3); Filled circles = group 3 which was the OA injury 
group (n = 7); Filled squares = group 4 which was the OA injury with 
late terbutaline infusion group (n = 6). *P < 0.05 early recovery versus 
late recovery in group 4 (OA + terbutaline) (intra-group comparison by 
analysis of variance and the post-hoc test of Tukey-Kramer). FITC-D70 
= fluorescein-labeled dextran; KAB = coefficient of capillary-alveolar 
leakage; OA = oleic acid.Critical Care    Vol 13 No 5    Briot et al.
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was no significant difference between groups at any stages of
the experiment.
Hemodynamic and gas exchange data of groups 3 and 4 are
summarized in Table 1.
Discussion
The main finding of this study is that the capillary-alveolar
transport of FITC-D70 is increased by terbutaline infusion
starting 90 minutes after the onset of an OA-induced lung
injury. The participation of a terbutaline-induced increase in
CO and PAP is suspected in the aggravation of lung injury.
Methodological considerations
Our technique of capillary-alveolar permeability measurement
modified a BAL technique previously described [17] and now
allow the permeability to be monitored over extended periods
of time. This new method has been fully described in a prior
publication [6] and will be only briefly discussed here. This
technique allows sampling of a lung segment saturated with
BAL fluid every 15 minutes. Our BAL sampling technique
offers a higher frequency of measurements and a greater sen-
sitivity compared with the other techniques of lung permeabil-
ity measurement either by lung lymph collection or the external
radio-detection. This method differs also from the measure-
ment of alveolar fluid clearance, which reflects the alveolar epi-
thelium function, but variations are not necessarily correlated
with the permeability to proteins of the capillary-alveolar barrier
[18].  KAB, our transport rate coefficientof FITC-D70 from
blood to alveoli, reflects the sum of capillary endothelial, inter-
stitial and alveolar epithelial permeabilities arranged as resist-
ances in series. It reflects also the perfusion surface area of
lung capillaries. In normal conditions, thistransport rate coeffi-
cientis near zero. In this study, the time course and the values
Table 1
Hemodynamic and gas exchange data in groups 3 and 4
Mean ± SEM Steady state
30 - 75 min
Peak
75 - 120 min
Early recovery
120 - 180 min
Late recovery
180 - 240 min
ABP (mmHg)
Group 3 95.4 ± 4.3 75.3 ± 9.0 84.7 ± 7.8 102.8 ± 3.3
Group 4 93.0 ± 8.1 82.5 ± 4.6 93.8 ± 8.3 91.3 ± 3.1
Cardiac index (L/min/kg)
Group 3 0.16 ± 0.01 0.09 ± 0.01 0.10 ± 0.01 0.12 ± 0.01
Group 4 0.14 ± 0.01 0.13 ± 0.01 0.13 ± 0.09 0.24 ± 0.02 *
PAP (mmHg)
Group 3 17.1 ± 1.2 13.2 ± 1.3 15.2 ± 1.3 18.5 ± 1.8
Group 4 17.9 ± 1.9 18.4 ± 1.4 18.2 ± 1.5 24.2 ± 0.9 *
Pcap (mmHg)
Group 3 10.5 ± 1.5 10.5 ± 1.5 9.7 ± 1.1 10.3 ± 0.5
Group 4 12.6 ± 1.6 14.0 ± 1.1 13.2 ± 1.3 15.6 ± 1.2
PAOP (mmHg)
Group 3 6.9 ± 0.6 6.3 ± 0.9 6.0 ± 1.0 6.0 ± 0.4
Group 4 9.4 ± 1.5 9.3 ± 1.0 9.0 ± 1.7 10.0 ± 0.7
PVR (mmHg/L/min/kg)
Group 3 63.7 ± 7.6 76.8 ± 5.5 92.0 ± 10.2 104.1 ± 12.6
Group 4 60.7 ± 11.5 70.1 ± 15.1 71.3 ± 12.1 58.9 ± 11.5 *
PaO2/FiO2 (kPa)
Group 3 36.2 ± 0.7 14.5 ± 4.4 10.5 ± 2.9 10.8 ± 3.7
Group 4 27.9 ± 2.0 16.6 ± 2.7 15.3 ± 3.2 15.2 ± 3.1
ABP = systemic arterial blood pressure; FiO2 = fraction of inspired oxygen; PaO2 = partial pressure of oxygen in arterial blood; PAOP = 
pulmonary arterial occlusion pressure; PAP = pulmonary arterial blood pressure; Pcap = pulmonary capillary pressure; PVR = total pulmonary 
vascular resistances; SEM = standard error of the mean.
Group 3 = OA injury without terbutaline (n = 7); Group 4 = OA + terbutaline (n = 6); * P < 0.05 early recovery versus late recovery in group 4 
(OA + terbutaline) (intra-group comparison by analysis of variance and the post-hoc test of Tukey-Kramer).Available online http://ccforum.com/content/13/5/R166
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of KAB after OA injury were consistent with our prior findings
[6] with a peak of injury followed by a slow recovery period. In
this new series we studied specifically the effects of a terbuta-
line infusion started 90 minutes after OA injury. The terbutaline
administration aggravated the capillary-alveolar transport of
FITC-D70.
Possible explanations for the observed terbutaline 
effects
The capillary-interstitial macromolecular flow through the
endothelial barrier is essentially convective (i.e., drawn by cap-
illary fluid filtration) when the endothelium is injured [19]. This
elevation in convective transport can result from a decrease in
the reflection coefficient for proteins of the capillary-alveolar
barrier, or from an increase in capillary fluid filtration.
It is unlikely that the terbutaline diminished the reflection coef-
ficient for proteins of the membrane. Indeed β-agonists are
known for their anti-inflammatory effects and for improving the
tightness of the endothelial cells [7,8].
Although β2-adrenergic agonists, such as terbutaline, stimu-
late water clearance by epithelial cells [10], we rule out a sig-
nificant participation of fluid reabsorption in the post
terbutaline rebound of FITC-D70 transport. Our BAL sampling
process is designed to ensure a high alveolar fluid renewal
(48%/h; see calculations in the Additional data file 1), largely
higher than the potential alveolar epithelial fluid reabsorption,
even when enhanced by terbutaline. On the other hand, terb-
utaline may have increased the fluid filtration through an eleva-
tion of the capillary pressure or an augmentation of the
perfusion surface area. Indeed, our data have shown signifi-
cant correlations in group 4 (OA + terbutaline) between the
coefficient of FITC-D70 leakage KAB and Pcap, cardiac index
and PAP (Figure 3).
We observed a non-significant trend towards an increased
Pcap after terbutaline administration as compared with the
early recovery period. In normal lung, an increase in Pcap
leads to a large elevation in transvascular fluid filtration but a
minor elevation in transvascular protein filtration [20]. In con-
trast, in lung injury entailing altered capillary-alveolar permea-
bility, any increase in Pcap induces a large elevation in both
transvascular fluid and protein filtration [21].
Terbutaline may also have increased the perfusion surface
area and recruited leaky injured capillaries, which were initially
derecruited by the hypoxic vasoconstriction. Several argu-
ments plead in favor of this hypothesis. After terbutaline
administration we observed a marked increase in cardiac index
which is a well-known effect of the β-agonists. In normal lung,
an increase in CO does not induce, by itself, an increase in
transvascular fluid and protein filtration [22]. In contrast, in an
OA-injured lung, increasing CO may worsen lung water accu-
mulation likely by pulmonary vascular recruitment [23]. We
also observed a significant reduction in PVR after terbutaline
administration. Indeed, while OA injury initially elevated PVR,
terbutaline administration reduced these elevated resistances
to pre-injury levels. This drop in PVR, together with the
increase in cardiac index, is consistent with an increase in per-
fusion surface area related to terbutaline infusion. b2-agonists
Figure 3
Correlations of KAB in group 4 (OA + terbutaline) Correlations of KAB in group 4 (OA + terbutaline). Individual correla-
tions in group 4 (OA + terbutaline) (a) between the FITC-D70 leakage 
index KAB and capillary pressure; (b) between KAB and cardiac index; 
and (c) between KAB and mean Pulmonary Arterial Pressure (by linear 
regression). FITC-D70 = fluorescein-labeled dextran; KAB = coefficient 
of capillary-alveolar leakage; OA = oleic acid.Critical Care    Vol 13 No 5    Briot et al.
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are pulmonary vasodilators and terbutaline may also have lifted
the hypoxic vasoconstriction and increased blood flow in
injured lung zones, resulting in increased protein transport.
Therefore, we speculate that the rebound in FITC-D70 leak-
age, observed in our series during terbutaline perfusion, was
provoked by an increase in perfusion surface area, associated
to a small elevation of the Pcap.
Recruitment of 'blind capillaries'
OA injury induces a hypoxic and mediator-induced active
vasoconstriction, a perivascular compression by edema, and
an intravascular obstruction by thromboembolism or endothe-
lial swelling [24,25]. The active vasoconstriction is a pre-cap-
illary and protective phenomenon. It accounts for
approximately 50% of the pulmonary hypertension and is par-
tially reversible. Eliminating this adaptive vasoconstriction
response may dramatically deteriorate OA-injured lungs
[26,27]. Several studies in intact dogs [28,29] have shown an
increase in pulmonary venous resistance following OA injury.
In the present study we also observed a trend, although not
significant, towards an increase in pulmonary venous resist-
ance during the peak of OA injury. This enhancement in post-
capillary pulmonary venous resistance after OA injury may be
mediated by thromboxane A2 release [30], sympathetic vaso-
constriction [29], or microvascular obstruction [31]. Anglade
and colleagues [32] have shown in OA-injured rabbit lung
preparations that the increase in filtration surface area and
capillary recruitment is larger when entailed by an elevation in
CO than by an elevation in pulmonary venous pressure. These
authors hypothesized that an elevation in CO could result in
the re-opening of non-flowing leaky capillaries in zone 1, called
'blind capillaries' (i.e. opened at their arterial end and
obstructed at their venous end) with a filtration pressure at the
level of arteriolar pressure (Figure 4). This hypothesis is con-
sistent with the observations of positron emission tomography
(PET) imaging in OA injury, showing a greater reduction in
blood flow in the most injured areas [33]. The injured capillar-
ies are highly permeable vessels and their recruitment may
considerably increase fluid and protein leak upstream of the
obstruction.
In the present study, we speculate that the rebound of capil-
lary-alveolar leakage, observed after terbutaline infusion, is
consistent with the hypothesis of an arterial re-opening of blind
injured capillaries in zone 1. Also, the elevation in CO and in
PAP may have shifted downstream the obstruction point under
zone 2 conditions towards the venous ends of capillaries and
venules (Figure 4).
Limitations of the study
Our preparation was designed only to study the early phase of
the lung injury. BAL is known to cause a depletion in alveolar
surfactant [34] and increase the recruitment of neutrophils
[35,36], but it does not cause a significant change in the pro-
tein permeability of the epithelial barrier during the first four
hours [37]. In the same manner, in our data, we observed a
spontaneous aggravation of lung permeability, in control ani-
mals, when the experiments were prolonged beyond four
hours [6]. Therefore, the BAL technique cannot be extended
over a long period. Due to this time limitation, we cannot
exclude that the rebound of FITC-D70 leakage, observed with
terbutaline infusion, might be only a transient side effect of
terbutaline, lately counterbalanced by β-agonist beneficial
effects. Other studies have shown that β2-agonist action on
capillary-alveolar membrane may be delayed for several hours.
Figure 4
Recruitment of blind capillaries Recruitment of blind capillaries. Adapted from Anglade and colleagues 
[32] with permission. Model of circulation includes four branches of 
pulmonary circulation lying in parallel in same horizontal plane. Flow-lim-
iting compression point in zone 2 lung is indicated by narrowing of vas-
cular branch. (a) OA-injured lung before the terbutaline-increase in 
cardiac index and PAP. (b) Filling of blind vessels in zone 1, (i.e., 
opened at their arterial end and obstructed at their venous end). Corre-
sponding injured capillaries may filter considerably (arrows) because fil-
tration pressure in these non-flowing capillaries is at the level of 
pulmonary arteriolar pressure. In addition steep pressure gradient 
observed during increased cardiac index may also move downstream 
the obstruction point in zone 2 lung and increase filtration surface area. 
OA = oleic acid; PAP = pulmonary arterial blood pressure.Available online http://ccforum.com/content/13/5/R166
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McAuley and colleagues [9] have observed a positive effect of
salmeterol four hours, but not two hours, after the onset of an
hydrochloric acid (Hcl) lung injury in rats. In the two recent
large clinical studies on β2-agonist treatment in ARDS (BALTI
[11] and ALTA [12]), patients were recruited approximately 24
hours after the beginning of lung injury and in the BALTI study,
intravenous infusion of salbutamol reduces extravascular lung
water in patients after a 72-hour delay.
Such delayed action might explain the lack of efficacy of terb-
utaline on capillary-alveolar permeability in our series. Other
studies should be specially designed to evaluate the terbuta-
line effects beyond the first four hours following OA injury.
The OA injury model is also, by itself, a limitation of our study.
OA is known to provoke a severe injury that probably over-
whelmed the beneficial effects of β-agonists on capillary-alve-
olar permeability or edema fluid reabsorption. An aggravation
of lung injury after an elevation in pulmonary blood flow has
been frequently described in direct injuries of the lung such as
OA injury [15,23,28,32]. In contrast, indirect lung injuries sec-
ondary to endotoxin infusion or severe sepsis seem to be less
sensitive to variations in pulmonary blood flow and can be
improved by β2-agonist therapies [38-40].
A final limitation of our study is the intravenous mode of terbu-
taline administration which may have provoked more hemody-
namic effects than other routes. Aerosolized administration
has been proposed to limit the systemic effects of the β2-ago-
nists [41]. Atabai and colleagues [42] have shown that physi-
ologically effective alveolar concentrations of salbutamol (10-6
M) may be delivered with conventional systems in patients with
pulmonary edema. However, the recent ALTA study [12] failed
to find a beneficial effect of aerosolized albuterol therapy in a
large randomized, placebo-controlled trial.
Clinical implications
For everyday practice, our animal model may suggest that ther-
apies inducing an increase in CO and a decrease in PVR have
the potential to heighten the early increase in protein transport
from plasma to alveoli within the acutely injured lung. Moreo-
ver, the removal of proteins from alveolar space is much slower
than alveolar fluid clearance [43]. This accumulation of plasma
proteins may contribute to the development of fibroprolifera-
tion [1] and lung fibrosis, which contribute to a negative out-
come [2]. Our data are consistent with the notion, recently
emphasized by experimental [15] and clinical [44] publica-
tions, that the vascular side of the capillary-alveolar membrane
cannot be ignored.
Conclusions
Our BAL technique allowed the monitoring of the time course
of capillary-alveolar barrier leakage of macromolecules and it's
recovery in a pre-clinical model of ARDS. We found that an
infusion of terbutaline, started 90 minutes after the onset of
OA injury, increased capillary-alveolar transport of FITC-D70.
We speculate that the hemodynamic effects of terbutaline,
may have contributed to this increased leakage of macromole-
cules, and to the recruitment of leaky capillaries thereby
increasing the capillary exchange surface area. These findings
suggest that therapies inducing an increase in CO and a
decrease in PVR have the potential to heighten the early
increase in protein transport from plasma to alveoli within the
acutely injured lung.
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Key messages
￿  Capillary-alveolar permeability to macromolecules 
(FITC-D70) was measured every 15 minutes for 3 
hours, in an OAARDS model in anesthetized dogs.
￿  The time course of injury showed a peak of permeability 
30 minutes after the OA infusion, followed by a slow 
recovery.
￿  A treatment by terbutaline intravenous infusion, started 
90 minutes after the onset of OA injury, increased capil-
lary-alveolar permeability to FITC-D70.
￿  Hemodynamic effects of terbutaline, may have recruited 
leaky capillaries and increased the capillary exchange 
surface area.
￿  Therapies inducing an increase in CO and a decrease 
in PVR may aggravate the protein leakage from plasma 
to alveoli within the acutely injured lung.Critical Care    Vol 13 No 5    Briot et al.
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